Genitourinary Cancer Research - Penn State Cancer Institute
Genitourinary Cancer Research
Research into genitourinary and prostate cancer at Penn State Cancer Institute is conducted by the genitourinary cancer team. See current clinical trials and members of that team here.
Clinical Trials
The COVID-19 and Cancer Consortium (CCC19) Registry
Phase III Study of PET-Directed Local or Systemic Therapy Intensification in Prostate Cancer Patients with Post-Prostatectomy Biochemical Recurrence
Psychosocial Challenges and Educational/Occupational Aspirations of Adolescent/Young Adult Cancer Survivors
Multicenter Phase 3 Pivotal Study to Evaluate the Safety and Efficacy of TOOKAD (padeliporfin) Vascular Targeted Photodynamic Therapy in the Treatment of Low Grade Upper Tract Urothelial Cancer
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology Agents in Subjects With Unresectable Advanced or Metastatic Solid Tumors
Genomic profiling of urothelial cancers
Evaluate Safety and Efficacy of Daily oral Angelica gigas Nakai (AGN)-INM176 in Prostate Patients with Rising Plasma PSA (Phase I/II trial)
Phase 1, open label clinical trial to treat Stage IV cancer patients with multiple patient-specific mutated cell surface proteins with chimeric antibodies
EA8231- A Phase III Randomized Trial of Pembrolizumab in Combination with Sacituzumab Govitecan vs Standard of Care in Anti-PD(L)1-Resistant Advanced Urothelial Cancer
NRG-GU013: The Phase III 'High Five Trial' Five Fraction Radiation for High-Risk Prostate Cancer
A Phase 1, Open-Label, Multicenter Study of Janx007 in Subjects with Metastatic Castration-Resistant Prostate Cancer
A Randomised, Double-blind, Placebo-controlled, Phase III Study of Adjuvant Saruparib (AZD5305) in Patients with BRCAm Localised High-Risk Prostate Cancer Receiving Radiotherapy with Androgen Deprivation Therapy (EvoPAR-Prostate02)
NRG-GU014: Randomized Phase Ii Trial of Pembrolizumab And Radiation vs. Radiation and Concurrent Chemotherapy for High-Grade T1 Bladder Cancer (PARCCTrial)
Phase 3, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-104, a Novel Formulation of UGN-101, for the Treatment of Patients With Low-grade Upper Tract Urothelial Cancer (LG-UTUC)
A Phase 2 Multi-Arm, Multi Cohort, Open Label Study To Evaluate The Safety And Efficacy Of Cretostemogene Grenadenorepvec In Participants With High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC)
NRG-GU012: Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) For Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)
Disease Team Members
| First Name | Last Name | Title | Role | ||
|---|---|---|---|---|---|
 |
Joseph | Drabick | MD | ||
 |
Monika | Joshi | MD, MRCP | ||
 |
Matthew G. | Kaag | MD | ||
 |
Jay | Raman | MD | ||
 |
Nabeel | Sarwani | MD | ||
 |
Leonard | Tuanquin | MD |
Research into genitourinary and prostate cancer at Penn State Cancer Institute is conducted by the genitourinary cancer team. See current clinical trials and members of that team here.
The COVID-19 and Cancer Consortium (CCC19) Registry
Phase III Study of PET-Directed Local or Systemic Therapy Intensification in Prostate Cancer Patients with Post-Prostatectomy Biochemical Recurrence
Psychosocial Challenges and Educational/Occupational Aspirations of Adolescent/Young Adult Cancer Survivors
Multicenter Phase 3 Pivotal Study to Evaluate the Safety and Efficacy of TOOKAD (padeliporfin) Vascular Targeted Photodynamic Therapy in the Treatment of Low Grade Upper Tract Urothelial Cancer
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology Agents in Subjects With Unresectable Advanced or Metastatic Solid Tumors
Genomic profiling of urothelial cancers
Evaluate Safety and Efficacy of Daily oral Angelica gigas Nakai (AGN)-INM176 in Prostate Patients with Rising Plasma PSA (Phase I/II trial)
Phase 1, open label clinical trial to treat Stage IV cancer patients with multiple patient-specific mutated cell surface proteins with chimeric antibodies
EA8231- A Phase III Randomized Trial of Pembrolizumab in Combination with Sacituzumab Govitecan vs Standard of Care in Anti-PD(L)1-Resistant Advanced Urothelial Cancer
NRG-GU013: The Phase III 'High Five Trial' Five Fraction Radiation for High-Risk Prostate Cancer
A Phase 1, Open-Label, Multicenter Study of Janx007 in Subjects with Metastatic Castration-Resistant Prostate Cancer
A Randomised, Double-blind, Placebo-controlled, Phase III Study of Adjuvant Saruparib (AZD5305) in Patients with BRCAm Localised High-Risk Prostate Cancer Receiving Radiotherapy with Androgen Deprivation Therapy (EvoPAR-Prostate02)
NRG-GU014: Randomized Phase Ii Trial of Pembrolizumab And Radiation vs. Radiation and Concurrent Chemotherapy for High-Grade T1 Bladder Cancer (PARCCTrial)
Phase 3, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-104, a Novel Formulation of UGN-101, for the Treatment of Patients With Low-grade Upper Tract Urothelial Cancer (LG-UTUC)
A Phase 2 Multi-Arm, Multi Cohort, Open Label Study To Evaluate The Safety And Efficacy Of Cretostemogene Grenadenorepvec In Participants With High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC)
NRG-GU012: Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) For Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)
| First Name | Last Name | Title | Role | ||
|---|---|---|---|---|---|
|
Joseph | Drabick | MD | ||
|
Monika | Joshi | MD, MRCP | ||
|
Matthew G. | Kaag | MD | ||
|
Jay | Raman | MD | ||
|
Nabeel | Sarwani | MD | ||
|
Leonard | Tuanquin | MD |